Mustang Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.4001 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.03M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Details
| Name | Mustang Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 4 |
| Founded | 2015 |
| Ceo | Manuel Litchman |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US62818Q3020 |
| Cusip | 62818Q302 |
| Cik | 0001680048 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Manuel Litchman M.D. | President, Chief Executive Officer, Interim Chief Financial Officer and Director |
| Michael S. Weiss Esq., J.D. | Executive Chairman |
| Peter Carney | Controller and Interim Chief Accounting Officer |
| Greg Furrow M.S. | Chief Quality Officer |
| Robyn M. Hunter | Corporate Secretary |
Contact
| Address | 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, United States |
| Phone | 781 652 4500 |
| Website | https://www.mustangbio.com |